Rapid Clearance of Refractory Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia With Septic Pulmonary Emboli Following Early Ceftaroline Therapy

早期头孢洛林治疗后,难治性耐甲氧西林金黄色葡萄球菌(MRSA)菌血症伴脓毒性肺栓塞迅速清除

阅读:1

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with significant morbidity and mortality, particularly when persistent despite appropriate therapy. Refractory bacteremia often reflects inadequate source control, metastatic infection, or antimicrobial treatment failure and requires timely reassessment and escalation of care. We report the case of a 44-year-old male patient with poorly controlled type 2 diabetes mellitus and polysubstance use who presented with altered mental status and was found to have diabetic ketoacidosis, necrotizing soft tissue infection of the right lower extremity, and MRSA bacteremia. His hospital course was complicated by septic pulmonary emboli and lung abscesses. Despite prompt initiation of intravenous vancomycin, therapeutic drug levels, and definitive surgical source control via below-knee amputation, surveillance blood cultures remained persistently positive for MRSA. Following multidisciplinary evaluation, vancomycin was discontinued and intravenous ceftaroline was initiated, resulting in rapid clearance of bacteremia and sustained clinical improvement. The patient was discharged to a skilled nursing facility to complete a six-week course of ceftaroline, with no evidence of recurrent infection on follow-up. This case underscores the importance of early recognition of vancomycin failure in persistent MRSA bacteremia and highlights the role of ceftaroline as an effective salvage therapy, particularly in patients with metastatic infection and high-risk comorbidities. Multidisciplinary management and individualized antimicrobial strategies remain critical for achieving favorable outcomes in refractory MRSA infections.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。